Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
CAR T cell therapy has transformed the treatment of B cell cancers and is now being pursued by biotech companies for conditions as varied as systemic lupus erythematosus, diabetes and organ rejection.
Many countries are short of healthcare workers, thousands of whom have quit since the COVID-19 pandemic, but the global migration of doctors and nurses to work in high-income countries is hurting the world’s poorest people.
Social determinants of health can only be tackled through collaborations between public health leaders, economists, sociologists, and other non-medical stakeholders, as well as involvement from the community.
Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.
DigiONE is a pilot European learning health system in precision oncology that aims to identify optimal cancer treatments by learning from every patient, not just those in trials, through privacy-preserving interrogation of their standardized routine electronic health records.
A six-tiered governance framework for federated health data, with varying levels of data access and sharing, is proposed to facilitate the use of health data held within more than one secure environment, while preserving privacy.
Therapeutic genome editing has great potential to cure some rare diseases, but germline editing is banned. With a broad societal discussion supported by national and transnational legislation, it could be allowed in certain circumstances.
A focus on maternal mortality reduction and time-restricted follow-ups after childbirth has led to neglect of long-term labor and birth complications experienced by women.
GLP-1 receptor agonists are effective treatments for obesity but are less accessible worldwide than pharmacological treatments for diabetes, reflecting biases and lack of education, and perpetuating health inequalities.